Risk Factors for Coronary Heart Disease in Women With Systemic Lupus Erythematosus: The Toronto Risk Factor Study

Arthritis and Rheumatism

Volumn 48, Issue 11, 2003, Pages 3159-3167

  Bruce, Ian N ^a   Urowitz, Murray B ^a,b   Gladman, Dafna D ^a   Ibañez, Dominique ^b   Steiner, George ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; HOMOCYSTEINE; STEROID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CANADA; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL EXAMINATION; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; HIGH RISK POPULATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFESTYLE; MAJOR CLINICAL STUDY; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; CORONARY DISEASE; FEMALE; HOMOCYSTEINE; HUMANS; LIPOPROTEINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; ONTARIO; RISK; RISK FACTORS;

EID: 0242495176     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.11296     Document Type: Article

References (46)

1. Urowitz MB, Bookman AAM, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality in systemic lupus erythematosus. Am J Med 1976;60:221-5.
2. Gladman DD, Urowitz MB. Morbidity in systemic lupus erythematosus. J Rheumatol 1987;14 Suppl 13:223-6.
3. Petri M, Perez-Gutthan S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992;93:513-9.
4. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol 1997;145:408-15.
5. Bruce IN, Gladman DD, Urowitz MB. Premature atherosclerosis in SLE. Rheum Dis Clin North Am 2000;26:257-78.
6. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999;42:338-46.
7. Ilowite NT, Samuel P, Ginzler E, Jacobson MS. Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 1988;31:859-63.
8. Borba EF, Bonfa E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease activity and anticardiolipin antibodies. Lupus 1997;6:533-9.
9. Petri M, Lakatta C, Magder L, Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal analysis. Am J Med 1994;96:254-9.
10. Hearth-Holmes M, Baethge BA, Broadwell L, Wolf RE. Dietary treatment of hyperlipidemia in patients with systemic lupus erythematosus. J Rheumatol 1995;22:450-4.
11. MacGregor AJ, Dhillon VB, Binder A, Forte CA, Knight BC, Betteridge DJ, et al. Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. Ann Rheum Dis 1992;51:152-5.
12. Murai A, Miyahara T, Fujimoto N, Matsuda M, Kameyama M. Lipoprotein(a) as a risk factor for coronary artery disease and cerebral infarction. Atherosclerosis 1986;260:1655-60.
13. Borba EF, Santos RD, Bonfa E, Vinagre CG, Pillegi FJC, Cossermelli W, Maranhao RC. Lipoprotein(a) levels in systemic lupus erythematosus. J Rheumatol 1994;21:220-3.
14. Petri M, Rubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996;348: 1120-4.
15. Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the Johns Hopkins Lupus cohort: prevalence, recognition by patients and preventive practices. Medicine 1992;71:291-302.
16. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
17. Lee P, Urowitz MB, Bookman AA, Koehler BE, Smythe HA, Gordon DA, et al. Systemic lupus erythematosus: a review of 110 patients with reference to nephritis, the nervous system, infections, aseptic necrosis and prognosis. Q J Med 1977;46:1-32.
18. Gladman DD, Ibañez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 2002;29:288-91.
19. Ibañez D, Urowitz MB, Gladman DD. Disease activity over time: the adjusted mean and variability measure [abstract]. J Rheumatol 2001;28:1419.
20. Kamel WB, Sorlie P. Some health benefits of physical activity: the Framingham study. Arch Intern Med 1979;139:857-61.
21. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269: 3015-23.
22. Redgrave TG, Carlson LA. Changes in plasma very low density and low density content, composition and size after a fatty meal in normal and hypertriglyceridemic men. J Lipid Res 1979;20:217-29.
23. Friedewald WT, Levy RI, Frederickon DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
24. Krauss RM, Blanche PJ. Detection and quantitation of LDL subfractions. Curr Opin Lipid 1992;3:377-83.
25. Pagnan A, Havel R, Kane J, Kotite L. Characterization of human very low density lipoproteins containing two electrophoretic populations: double pre-beta lipoproteinemia and primary dysbetalipoproteinemia. J Lipid Res 1977;18:613-22.
26. Evrovski J, Callaghan M, Cole DE. Determination of homocysteine by HPLC with pulsed integrated amperometry. Clin Chem 1995;41:757-8.
27. Fodor JG, Frohlich JJ, Genest JJG Jr, McPherson PR. Recommendations for the management of treatment of dylipidemia: report of the Working Group on Hypercholesterolemia and Other Dylipidemias. CMAJ 2000;162:1441-7.
28. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331-7.
29. Gladman DD, Urowitz MB. Systemic lupus erythematosus: clinical features. In: Klippel JH, Dieppe PA, editors. Rheumatology. 2nd ed. St. Louis: Mosby; 1998. p. 7:1.1-1.18.
30. Choinière R, Lafontaine P, Edwards AC. Distribution of cardiovascular disease risk factors by socioeconomic status among Canadian adults. CMAJ 2000;162 Suppl 9:S13-24.
31. Pyne D, Isenberg DA. Autoimmune thyroid disease in systemic lupus erythematosus. Ann Rheum Dis 2002;61:70-2.
32. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
33. Tench C, Bentley D, Vleck V, McCurdie I, White P, D'Cruz D. Aerobic fitness, fatigue, and physical disability in systemic lupus erythematosus. J Rheumatol 2002;29:474-81.
34. Daltroy LH, Robb-Nicholson C, Iversen MD, Wright EA, Liang MH. Effectiveness of minimally supervised home aerobic training in patients with systemic rheumatic disease. Br J Rheumatol 1995;34:1064-9.
35. Rahman P, Urowitz MB, Gladman DD, Bruce IN, Genest J Jr. Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol 1999; 26:2363-8.
36. Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990;89:322-6.
37. Rahman P, Gladman DD, Urowitz MB, Yuen K, Hallett D, Bruce IN. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 1999;26:325-30.
38. Korhonen T, Savolainen MJ, Koistinen MJ, Ikaheimo M, Linnaluoto MK, Kervinen K, et al. Association of lipoprotein cholesterol and triglycerides with the severity of coronary artery disease in men and women. Atherosclerosis 1996;127:213-20.
39. Gotto AM Jr. Triglyceride as a risk factor for coronary artery disease. Am J Cardiol 1998;82:22-50.
40. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
41. Van den Brandhof WE, Haks K, Schouten EG, Verhoef P. The relation between plasma cysteine, plasma homocysteine and coronary atherosclerosis. Atherosclerosis 2001;157:403-9.
42. Bruce IN, Urowitz MB, Gladman DD, Hallet DC. Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 1999;26:2137-43.
43. Rahman P, Aguero S, Gladman DD, Hallett D, Urowitz MB. Vascular events in hypertensive patients with systemic lupus erythematosus. Lupus 2000;9:672-5.
44. Bruce IN, Gladman DD, Urowitz MB. Detection and modification of risk factors for coronary artery disease in patients with systemic lupus erythematosus: a quality improvement study. Clin Exp Rheumatol 1998;16:435-40.
45. Bray GA, Gray DS. Treatment of obesity: an overview. Diabetes Metab Rev 1988;4:653-79.
46. Wilson PWF, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaeffer EJ. Apolipoprotein E alleles, dyslipidemia and coronary heart disease. JAMA 1994;272:1666-71.